Unity Biotechnology Inc (UBX)

$2.47 0.12 (4.63%)

14:25 EDT UBX Stock Quote Delayed 30 Minutes

Why Is Unity Biotechnology (UBX) Stock Down 52% Today?

By William White, InvestorPlace Writer Mar 27, 2023

Unity Biotechnology (UBX) stock is taking a beating on Monday after revealing results from its Phase 2 clinical trial of UBX1325.

Unity Biotechnology (UBX) Stock Pops on Positive Study Data

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

The Three Best Anti-Aging Stocks to Buy in September

More Articles

Volume:

Previous Close -

Market Cap 36.07M

PE Ratio -0.70

EPS -3.51

Volume (Avg. Vol.) 17,228

Day's Range $2.47 - $2.54

52-Week Range $1.46 - $5.72

Dividend & Yield N/A (N/A)

UBX Stock Predictions, Articles, and Unity Biotechnology Inc News

From InvestorPlace
From the Web

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

By William White, InvestorPlace Writer Aug 18, 2022

It's time to take a look at the biggest pre-market stock movers for Thursday and the news that's got those shares moving!

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

By William White, InvestorPlace Writer Aug 15, 2022

Good morning, investors! We're starting off the week with a breakdown of the biggest pre-market stock movers for Monday!

Why Is Unity Biotechnology (UBX) Stock Up 71% Today?

By William White, InvestorPlace Writer Aug 12, 2022

Unity Biotechnology (UBX) stock is surging higher on Friday following the release of its earnings report for the second quarter of 2022.

3 New Healthcare Stocks to Buy Right Now

By Aaron Levitt, InvestorPlace Contributor May 14, 2018

These new healthcare stocks could be great winners long term. As we continue to age and populations grow, demand for new and innovative healthcare solutions is only growing. That makes stocks in the healthcare sector a prime place to profit. Here's three picks to buy before they surge too high

Unity Biotech stock falls on Phase 2 data wet AMD data (NASDAQ:UBX)

From Seeking Alpha Mar 27, 2023

Unity Biotechnology (UBX) lost ~48% pre-market Monday after announcing that itswet AMD candidate UBX1325 failed to outperform Regeneron’s (REGN) Eylea. Read more here.

Wedbush Keeps Their Buy Rating on Unity Biotechnology (UBX)

From TipRanks Nov 10, 2022

In a report released today, Andreas Argyrides from Wedbush reiterated a Buy rating on Unity Biotechnology (UBX – Research Report), with a price target of $35....

H.C. Wainwright Remains a Buy on Unity Biotechnology (UBX)

From TipRanks Nov 9, 2022

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Unity Biotechnology (UBX – Research Report) today and set a price target of $10.00. The company...

Analysts Offer Insights on Healthcare Companies: Unity Biotechnology (UBX) and Axcella Health (AXLA)

From TipRanks Nov 2, 2022

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Unity Biotechnology (

H.C. Wainwright Keeps Their Buy Rating on Unity Biotechnology (UBX)

From TipRanks Nov 2, 2022

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Unity Biotechnology (UBX – Research Report), with a price target of $1...

Unity Bio Soars on Promising Phase 2 DME Data

From TipRanks Nov 1, 2022

Shares of biotechnology company Unity Biotechnology (NASDAQ:UBX) are flying high today on promising data from a Phase 2 study evaluating UBX1325 for the treatment o...